Verastem (VSTM) Cost of Revenue (2018 - 2026)

Verastem (VSTM) posted quarterly Cost of Revenue of $2.8 million for Q1 2026, up 6.13% quarter-over-quarter from $2.6 million in Q4 2025.

Analysis

Verastem (VSTM) Cost of Revenue (2018 - 2026) Analysis & Trends

Verastem's Cost of Revenue history runs 5 years deep, the most recent figure standing at $2.8 million for Q1 2026.

In Q1 2026, Cost of Revenue changed N/A year-over-year to $2.8 million; the TTM figure through Mar 2026 stood at $7.4 million (changed N/A YoY), while the FY2025 annual figure was $4.6 million, changed N/A from the prior year.
Cost of Revenue for Q1 2026 stood at $2.8 million, up from $2.6 million in the prior quarter.
The five-year high for Cost of Revenue was $2.8 million in Q1 2026, with the low at $318000.0 in Q2 2025.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Cost of Rev (Qtr)
1	Vertex Pharmaceuticals	139.31 Bn	131.46 Bn	2.84 Bn	489.20 Mn
2	Regeneron Pharmaceuticals	85.65 Bn	77.66 Bn	3.93 Bn	360.70 Mn
3	Argenx Se	63.46 Bn	58.27 Bn	1.37 Bn	145.00 Mn
4	Moderna	57.94 Bn	52.80 Bn	52.00 Mn	93.00 Mn
5	Revolution Medicines	44.05 Bn	44.05 Bn	-	-
6	BeOne Medicines	39.96 Bn	34.86 Bn	1.53 Bn	174.53 Mn
7	Alnylam Pharmaceuticals	35.16 Bn	31.85 Bn	992.69 Mn	298.26 Mn
8	Royalty Pharma	28.44 Bn	27.60 Bn	-	-
9	Insmed	27.32 Bn	26.16 Bn	358.27 Mn	67.21 Mn
10	Verastem	789.92 Mn	653.56 Mn	36.32 Mn	3.76 Mn

Historic Data

Download Data